Blood Biomarker Panels for the Early Prediction of Stroke‐Associated Complications by Faura Llorens, Julia et al.
Journal of the American Heart Association
J Am Heart Assoc. 2021;10:e018946. DOI: 10.1161/JAHA.120.018946 1
 
ORIGINAL RESEARCH
Blood Biomarker Panels for the Early 
Prediction of Stroke- Associated 
Complications
Júlia Faura , MSc; Alejandro Bustamante , MD, PhD; Silvia Reverté, PhD; Teresa García- Berrocoso, PhD; 
Mónica Millán, MD, PhD; Mar Castellanos , MD, PhD; Blanca Lara- Rodríguez, MD; Josep Zaragoza, MD; 
Oriol Ventura, MSc; María Hernández- Pérez, MD, PhD; Cecile van Eendenburg, MD; Pere Cardona, MD, PhD; 
Elena López- Cancio , MD, PhD; David Cánovas, MD, PhD; Joaquín Serena , MD, PhD; 
Marta Rubiera  , MD, PhD; Antoni Dávalos, MD, PhD; Joan Montaner , MD, PhD
BACKGROUND: Acute decompensated heart failure (ADHF) and respiratory tract infections (RTIs) are potentially life- threatening 
complications in patients experiencing stroke during hospitalization. We aimed to test whether blood biomarker panels might 
predict these complications early after admission.
METHODS AND RESULTS: Nine hundred thirty- eight patients experiencing ischemic stroke were prospectively recruited in 
the Stroke- Chip study. Post- stroke complications during hospitalization were retrospectively evaluated. Blood samples 
were drawn within 6 hours after stroke onset, and 14 biomarkers were analyzed by immunoassays. Biomarker values were 
normalized using log- transformation and Z score. PanelomiX algorithm was used to select panels with the best accuracy 
for predicting ADHF and RTI. Logistic regression models were constructed with the clinical variables and the biomarker 
panels. The additional predictive value of the panels compared with the clinical model alone was evaluated by receiver 
operating characteristic curves. An internal validation through a 10- fold cross- validation with 3 repeats was performed. 
ADHF and RTI occurred in 19 (2%) and 86 (9.1%) cases, respectively. Three- biomarker panels were developed as predic-
tors: vascular adhesion protein- 1 >5.67, NT- proBNP (N- terminal pro- B- type natriuretic peptide) >4.98 and d- dimer >5.38 
(sensitivity, 89.5%; specificity, 71.7%) for ADHF; and interleukin- 6 >3.97, von Willebrand factor >3.67, and d- dimer >4.58 
(sensitivity, 82.6%; specificity, 59.8%) for RTI. Both panels independently predicted stroke complications (panel for ADHF: 
odds ratio [OR] [95% CI], 10.1 [3– 52.2]; panel for RTI: OR, 3.73 [1.95– 7.14]) after adjustment by clinical confounders. The 
addition of the panel to clinical predictors significantly improved areas under the curve of the receiver operating charac-
teristic curves in both cases.
CONCLUSIONS: Blood biomarkers could be useful for the early prediction of ADHF and RTI. Future studies should assess the 
usefulness of these panels in front of patients experiencing stroke with respiratory symptoms such as dyspnea.
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Mortality of patients experiencing stroke in Europe ranges from 13% to 35%.1 Acute post- stroke complications, such as respiratory infections 
and cardiac complications, are major causes of death 
in patients experiencing acute stroke.2 Early detection 
and treatment of these medical complications might 
represent an opportunity to further improve the out-
come of these patients.3
Acute decompensated heart failure (ADHF) is de-
fined as a new onset or rapidly or gradual worsen-
ing of heart failure (HF) symptoms that require urgent 
therapy.4 A frequency of 17% of ADHF in acute stroke 
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patients has been reported, and this cardiac compli-
cation is a strong independent predictor of poor func-
tional outcome in these patients.5
Respiratory tract infection (RTI) represents a well- 
known complication in patients experiencing stroke, 
and its frequency is around 12%.6 RTIs are also linked 
with poor functional outcome of the patients, a pro-
longed length of stay in the hospital, and increased 
mortality up to 1 year.7
Both RTI and ADHF may have common symptoms 
such as dyspnea, and early chest radiograph may not 
show typical changes, so differentiating between the 2 
clinical conditions can be difficult in daily clinical prac-
tice. In this context, blood biomarkers might serve as a 
useful tool to identify those patients at the highest risk 
of developing these complications, as well as for the 
early differential diagnosis of post- stroke RTI or ADHF.
In this study, we aimed to test whether blood bio-
markers measured at admission might identify patients 
at the highest risk of RTI or ADHF.
METHODS
The present study represents a retrospective analysis 
of the patients experiencing ischemic stroke prospec-
tively recruited at the multicenter Stroke- Chip study.8 
Certified neurologists, blinded to the biomarker ana-
lytic results, retrospectively evaluated clinical records 
to determine the occurrence of post- stroke compli-
cations during hospitalization. The Stroke- Chip study 
protocol was approved by each recruiting center’s eth-
ics committee, and all patients or relatives gave written 
informed consent. The data that support the findings 
of this study are available from the corresponding au-
thor upon reasonable request.
Diagnosis of Post- Stroke Complications
ADHF was defined, according to American Heart 
Association Guidelines,9 as new onset of dyspnea 
and/or fatigue, together with fluid retention, which 
may lead to pulmonary, or splanchnic congestion or 
peripheral edema, in the absence of other causes of 
dyspnea.
RTIs were diagnosed according to the Centers for 
Disease Control and Prevention criteria.10 In summary, 
the diagnosis of RTI required the presence of fever 
(body temperature >38°C) or elevated white blood cell 
count (>1.2×1010/L) and evidence of organ- specific 
involvement (purulent sputum, pulmonary infiltrate, 
cough, etc) or a positive blood culture. RTIs were clas-
sified as upper RTI, lower RTI, and pneumonia. An 
abnormal chest radiograph was required for the diag-
nosis of stroke- associated pneumonia.
Blood Sample Collection and Biomarker 
Measurement
Samples were drawn at admission, within 6  hours 
after stroke onset, and before the administration of 
acute- phase therapies such as reperfusion. Blood 
was collected into EDTA tubes, centrifuged at 1500g 
for 15 minutes at 4°C, and plasma aliquots were frozen 
at −80°C until biomarker measurement.
A 14- biomarker panel was measured. This panel 
included insulin- like growth factor– binding protein- 3, 
tumor necrosis factor receptor- 1, growth- related on-
cogene- α, Fas ligand, heat shock 70  kDa protein- 8, 
NT- proBNP (N- terminal pro- B- type natriuretic eptide), 
d- dimer, interleukin- 6, von Willebrand factor (vWF), 
vascular adhesion protein- 1, endostatin, S100 calcium- 
binding protein B, apolipoprotein CIII, and neuron cell 
adhesion molecule. The selection of these biomark-
ers and the measurement methods were described 
previously.8
Biomarker values were log- transformed with a base 
of 10 and divided by the value of the control sample of 
each plate. Because of the high intra- assay variability 
CLINICAL PERSPECTIVE
What Is New?
• This is a retrospective study of a multicenter 
cohort with 938 patients experiencing is-
chemic stroke in which the measurement of 
14 biomarkers was performed with early blood 
samples, extracted in the first 6 hours after the 
episode.
• Two biomarker combinations add predictive 
value to the clinical models for the prediction of 
2 major complications after stroke: acute de-
compensated heart failure and respiratory tract 
infections.
What Are the Clinical Implications?
• These 2 biomarker panels, jointly with clinical 
variables, would be able to predict acute de-
compensated heart failure and respiratory tract 
infection in the first hours after stroke.
• This would allow clinicians to monitor the pa-
tients at the highest risk to experience these 
pathologies and treat them accordingly, reduc-
ing the length of stay and the mortality of these 
patients.
Nonstandard Abbreviations and Acronyms
ADHF acute decompensated heart failure
RTI respiratory tract infections
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for some of the molecules, all the values were stan-
dardized by means of Z score.
Statistical Analysis
Statistical analyses were conducted with Statistical 
Packages for Social Sciences (version 22; SPSS Inc., 
Chicago, IL) and R software (version 3.6.1; R Foundation 
for Statistical Computing, Vienna, Austria). Normality of 
the continuous variables was assumed because of the 
size of the sample according to the central limit theorem. 
The univariate analysis was performed using the χ2 test 
for categorical variables and t- test for continuous varia-
bles. Binary logistic regression models were developed. 
Putative confounders based on previous literature were 
added to the models to adjust them. Multicollinearity 
among the predictor variables has been checked with 
the variance inflation factor. Firth correction was applied 
(“logistf” package in R) when constructing the binary 
Table 1. Univariate Analysis for ADHF and RTI After Stroke
ADHF RTI
No (N=919) Yes (N=19) P Value No (N=852) Yes (N=86) P Value
Age, y 72.52 (±13) 81.1 (±13.5) <0.0001* 72.2 (±13) 77.2 (±12.3) 0.001†
Sex, female 420 (45.7) 11 (57.9) 0.291 388 (45.6) 42 (48.8) 0.572
Hypertension 675 (73.4) 13 (68.4) 0.624 617 (72.6) 69 (80.2) 0.127
Dyslipemia 451 (49.1) 9 (47.4) 0.883 421 (49.5) 38 (44.2) 0.345
Diabetes mellitus 237 (25.8) 2 (10.5) 0.184 214 (25.2) 25 (29.1) 0.430
Tobacco 149 (16.2) 3 (15.8) 0.999 144 (16.9) 8 (9.3) 0.067
Alcohol 64 (7) 1 (5.3) 0.999 64 (7.5) 1 (1.2) 0.027‡
Atrial fibrillation 318 (34.6) 11 (57.9) 0.035‡ 282 (33.2) 46 (53.5) <0.0001*
Coronary disease 145 (15.8) 7 (36.8) 0.023‡ 132 (15.5) 19 (22.1) 0.115
Previous stroke 158 (17.2) 5 (26.3) 0.353 144 (16.9) 18 (20.9) 0.351
Previous mRS 0 (0– 1) 1.5 (0– 3) 0.001* 0 (0– 1) 1 (0– 3) <0.0001*
Baseline NIHSS 9 (±7.3) 15 (±4.9) <0.0001* 8.5 (±7.1) 15.5 (±6) <0.0001*
TOAST
CE 330 (40.7) 11 (84.6) 0.050 337 (40.1) 46 (55.4) 0.007†
LAA 116 (14.3) 0 (0) 115 (13.7) 10 (12)
Lacunar 109 (11.9) 0 (0) 119 (14.1) 2 (2.4)
Undetermined 240 (29.6) 2 (15.4) 255 (30.3) 22 (26.5)
Other 15 (1.9) 0 (0) 15 (1.8) 3 (3.6)
In- hospital mortality 108 (9.9) 8 (42.1) <0.0001* 44 (5.2) 30 (34.9) <0.0001*
3- mo disability 366 (42.2) 16 (84.32) <0.0001* 221 (32.6) 67 (89.3) <0.0001*
Apolipoprotein CIII 4.02 (±0.97) 3.68 (±0.98) 0.144 4.01 (±0.98) 3.99 (±0.93) 0.778
d- dimer 4.08 (±0.95) 4.60 (±0.79) 0.020‡ 4.05 (±0.94) 4.53 (±0.93) <0.0001*
Endostatin 4.11 (±0.94) 4.50 (±0.89) 0.073 4.09 (±0.93) 4.35 (±1.08) 0.015‡
GROA 3.99 (±0.97) 3.96 (±0.87) 0.881 4.00 (±0.98) 3.94 (±0.93) 0.582
Interleukin- 6 4.00 (±0.96) 4.24 (±0.77) 0.265 3.95 (±0.94) 4.49 (±1.02) <0.0001*
NT- proBNP 4.12 (±0.95) 5.03 (±0.87) <0.0001* 4.11 (±0.95) 4.45 (±0.91) 0.001* 
VAP- 1 4.05 (±0.99) 4.79 (±1.05) 0.001* 4.05 (±0.98) 4.19 (±1.12) 0.199
vWF 4.02 (±0.97) 4.25 (±0.88) 0.306 3.97 (±0.97) 4.49 (±0.89) <0.0001*
IGFBP- 3 4.00 (±0.98) 3.91 (±1.07) 0.694 3.99 (±0.98) 4.10 (±1.05) 0.330
Fas ligand 3.96 (±0.99) 4.40 (±0.72) 0.056 3.95 (±0.99) 4.16 (±0.99) 0.065
TNF- R1 4.04 (±0.98) 4.36 (±0.52) 0.038‡ 4.04 (±0.97) 4.17 (±1.03) 0.235
NCAM 3.98 (±0.99) 4.36 (±0.76) 0.090 3.99 (±0.98) 3.91 (±1.03) 0.498
S100B 4.03 (±0.98) 3.72 (±0.87) 0.233 4.02 (±0.99) 3.95 (±0.91) 0.558
Hsc70 4.04 (±0.95) 4.18 (±1.09) 0.567 4.04 (±0.95) 4.13 (±0.92) 0.414
Values are reported as n (%) or mean (±SD). Biomarker values are standardized. ADHF indicates acute decompensated heart failure; CE, cardiac embolism; 
DBP, diastolic blood pressure; GROA, growth- related oncogene- α; Hsc70, heat shock 70 kDa protein- 8; IGFBP- 3, insulin- like growth factor- binding protein- 3; 
LAA, large- artery atherothrombosis; mRS, modified rankin scale; NCAM, neuron cell adhesion molecule; NIHSS, National Institutes of Health Stroke Scale; 
NTproBNP, N- terminal pro- B- type natriuretic peptide; RTI, respiratory tract infection; S100B, S100 calcium- binding protein B; SBP, systolic blood pressure; 
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logistic regression models for ADHF to minimize the esti-
mates of the coefficients, as there is a low rate of events.
To avoid overfitting the models with individual bio-
markers, the best biomarker combination for the pre-
diction of the defined complications was selected 
using PanelomiX algorithm,11 optimizing the combi-
nation by accuracy with a maximum of 3 biomarkers. 
The analyses for the selection of the best biomarker 
combination were carried out separately and inde-
pendently in each of the complications (ADHF and 
RTI). Briefly, PanelomiX uses the iterative combina-
tion of biomarkers and thresholds method to select 
thresholds for each biomarker that provide the optimal 
classification performance and studies the robustness 
of the constructed panels through receiver operating 
characteristic (ROC) curves and cross- validation, per-
forming a 10- fold cross- validation. After the 10- fold 
cross- validation and for the evaluation of the perfor-
mance, ROC curves of the cross- validation are built as 
the mean of centered predictions over the 10 cross- 
validation folds. Then, the ROC curve is compared 
through De Long’s method with the cross- validation of 
the individual biomarkers.
To evaluate the additional value of the selected bio-
marker combination to the logistic regression models 
with the clinical predictors, De Long’s method was used 
to compare areas under the curve of ROC curves. An 
internal validation of the constructed logistic regression 
models was performed through a 10- fold cross- validation 
with 3 repeats, evaluating the same parameters than in 
the cross- validation performed by PanelomiX. A P- value 
<0.05 was considered statistically significant in all tests.
RESULTS
Nine hundred thirty- eight patients experiencing is-
chemic stroke from the Stroke- Chip study were 
included in this analysis. ADHF occurred in 19 of 
these patients (2%) and RTI in 86 patients (9.1%). 
Nine patients were noted with both complications. 
Patients with 1 or both complications were older, 
had higher rates of atrial fibrillation, higher baseline 
National Institute of Health Stroke Scale score, and 
higher previous modified Rankin scale score. Higher 
rates of in- hospital mortality and 3- month disability 
(Table 1) were also reported in these groups of pa-
tients. Patients with ADHF also had higher rates of 
coronary disease, and patients with RTI had higher 
values of admission glycemia.
Among the analyzed molecules, patients with ADHF 
had higher plasma levels of d- dimer, NT- proBNP, tumor 
necrosis factor receptor- 1, and vascular adhesion pro-
tein- 1 than those without this complication, whereas 
patients with RTI had higher levels of d- dimer, endosta-
tin, interleukin- 6, NT- proBNP, and vWF compared with 
patients without this complication. The values of each bio-
marker and the clinical variables are reported in Table 1.
A panel including vascular adhesion protein- 1 >5.67, 
NT- proBNP >4.98, and d- dimer >5.38 was selected by 
the PanelomiX software as the most accurate for the 
prediction of ADHF. The panel was positive when any 1 
of the markers was above the cutoff (specificity, 71.5%; 
sensitivity, 89.5%). For the prediction of RTI, the software 
selected a panel including interleukin- 6>3.97, vWF >3.67, 
and d- dimer >4.58. In this case, the panel was positive 
when at least 2 of the markers were above the cutoff 
(specificity, 59.8%; sensitivity, 82.9%) (Figure 1). Of the 9 
patients with both complications, 7 were positive for both 
panels, 1 patient was positive for only the RTI panel, and 
the other patient was negative for both panels.
Two different binary logistic regression models were 
developed, one for each complication. The selected bio-
marker panels independently predicted ADHF and RTI, 
respectively (odds ratio [OR], 11.859 [95% CI, 2.67– 53.74], 
P=0.001 for ADHF; OR, 3.73 [1.95– 7.15], P<0.0001 for 
Figure 1. ROC curves of the biomarkers alone and in 
combination for each complication.
A, ROC curve for RTI biomarkers panel (black line), D- dimer 
(dotted line), vWF (gray) and interleukin- 6 (dashed line). B, ROC 
curve for ADHF biomarker panel (black line), VAP- 1 (dotted line), 
NT- proBNP (gray line), and d- dimer (dashed line). ADHF indicates 
acute decompensated heart failure; IL- 6, interleukin- 6; NT- 
proBNP, N- terminal pro- B- type natriuretic peptide; ROC, receiver 
operating characteristic; RTI, respiratory tract infection; VAP- 1, 
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RTI) after adjusting by selected clinical variables (Table 2). 
Age, sex, and National Institute of Health Stroke Scale 
were selected as confounders in both models because 
of their influence in the development of both compli-
cations.12 In case of ADHF, coronary disease was also 
added to the model, as it has been reported as a risk 
factor for ADHF.13 Multicollinearity was not detected in 
any of the models. The addition of the biomarker panels 
to the logistic regression models improved the accuracy 
of the clinical model for both complications in terms of 
area under the curve, from 0.80 (95% CI, 0.70– 0.88) to 
0.88 (95% CI, 0.83– 0.93) (P=0.038) in ADHF and; from 
0.78 (95% CI, 0.73– 0.82) to 0.81 (95% CI, 0.77– 0.88) 
(P=0.048) in the case of RTI (Table 2).
These increments of the area under the curve 
when adding the biomarker combinations to the 
clinical models were also observed after the internal 
validation of these results through a 10- fold cross- 
validation. The results of the cross- validation are 
shown in Table 2, and all the ROC curves are repre-
sented in Figure 2.
DISCUSSION
The present study demonstrates that the occurrence of 
2 common post- stroke complications during hospitali-
zation, ADHF and RTI, could be predicted at admission 
by using 2 different biomarker panels in combination 
with clinical factors.
The use of blood biomarkers for the prediction of 
post- stroke complications has generated increasing 
research in the past years.14,15 However, individual 
markers tested so far have not demonstrated enough 
predictive accuracy to be implemented in clinical 
practice. In this article, rather than testing individual 
markers, we tested automatically derived biomarker 
panels, which might be complementary tools to 
achieve a better prediction.16 In fact, biomarker pan-
els might be more valuable to reflect the complexity 
of the disease and its consequences, with several 
impaired biological pathways that might be reflected 
by automatically selected biomarkers. In fact, we ob-
tained 2 different biomarker panels with individual 
markers from diverse pathways implicated in stroke 
and post- stroke complications.
Of the biomarkers proposed for the ADHF predic-
tion after stroke, NT- proBNP has been widely associ-
ated with the diagnosis of ADHF.17 Vascular adhesion 
protein- 1, a marker of endothelial dysfunction, has also 
been related with congestive HF, being elevated in 
these patients when compared with controls,18 and an 
independent prognostic marker for mortality in chronic 
HF patients.19 d- dimer is a product of fibrin degrada-
tion. In healthy subjects, high levels of d- dimer have 
been associated with incident HF with reduced ejec-
tion fraction.20 Moreover, in patients with known HF, 
higher levels of d- dimer predicted mortality and inci-
dent atrial fibrillation.21
The proteins from the RTI biomarker panel are more 
related with the acute phase. An increase in the lev-
els of the proinflammatory cytokine interleukin- 6 in 
patients with stroke- associated pneumonia has been 








NIHSS at admission 1.09 (1.02– 1.16), P=0.006* 1.06 (1– 1.14), P=0.048† 1.12 (1.09– 1.16), P<0.0001‡ 1.10 (1.07– 1.14), P<0.0001‡
Age 1.04 (0.99– 1.11), P=0.07 1.02 (0.98– 1.08), P=0.26 1.02 (1– 1.04), P=0.02† 1.01 (0.99– 1.03), P=0.2
Coronary disease 3.24 (1.18– 8.44), P=0.02† 2.8 (1.01– 7.36), P=0.047† … …
Sex, female 1.36 (0.5– 3.83), P=0.52 1.16 (0.43– 3.26), P=0.76 0.8 (0.51– 1.35), P=0.38 0.8 (0.5– 1.3), P=0.37
Biomarker 
combination
… 10.1 (3– 52.2), P<0.0001‡ … 3.73 (2.06– 6.75), P<0.0001‡
ROC curve
AUC 0.80 (0.70– 0.88) 0.88 (0.83– 0.93) 0.78 (0.73– 0.82) 0.81 (0.77– 0.88)
De Long test … P=0.038† … P=0.048†
Cross- validation 
AUC
0.79 (0.72– 0.87) 0.87 (0.82– 0.92) 0.78 (0.74– 0.83) 0.82 (0.78– 0.85)
De Long test … P=0.02† … P=0.002*
The table represents the comparison between predictive models, with or without biomarker combinations. For logistic regression models, OR (95% CI) and 
P values are given. For the evaluation of the performance of the models, the AUC (95% CI) of the models without doing cross- validation and carrying out a 10- 
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reported,22– 24 which can predict the risk of stroke- 
associated infections and mortality. Regarding the other 
2 biomarkers of the panel, d- dimer has been associ-
ated with community- acquired pneumonia. Increased 
plasma levels of this molecule were correlated with the 
severity of the disease.25 vWF is the only protein that 
has not been related with RTIs previously. Its major bi-
ological functions are related with adhesion of platelets 
and factor VII protection.26 But in the past years, new 
functions of this molecule have emerged. Interactions 
between platelets and bacterial infections have been 
reported,27 as well as the role of vWF with the immune 
cells, as leukocyte extravasation.28
Our results, if confirmed, might have clinical impli-
cations. We propose 2 different biomarker panels that 
could predict at admission the appearance of ADHF 
and RTI after stroke. Both biomarker panels have a 
high sensitivity, resulting in a detection of most of the 
true- positive patients. After stroke onset, predicting 
these 2 complications could help clinicians to monitor 
and treat these 2 kinds of patients as early as possi-
ble. Consequently, with these 2 biomarker combina-
tions in clinical practice and the adequate tools to treat 
these patients, there could be a reduction of the in- 
hospital length of stay or even a decrease in mortality. 
In the case of RTI, there is no evidence that antibiotic 
prophylaxis prevents the onset of these infections or 
reduces the mortality of these patients,29 but whether 
selective antibiotic prophylaxis in high- risk patients or 
alternative prophylactic measures such as immuno-
modulatory therapies are effective is being studied.
As mentioned in the introduction, dyspnea is a 
common symptom of ADHF and RTI, and this can 
sometimes delay the diagnosis of the complication. 
We suggest that these 2 biomarker combinations 
could also be useful for the differentiation of both dis-
eases, and clinicians would have additional tools for 
an early diagnosis or treatment. But to confirm this hy-
pothesis, a prospective study measuring these mark-
ers in patients with dyspnea should be performed.
Figure 2. Performance of the constructed models for the 2 complications.
A and B represent the performance of the models constructed for RTI, and C and D represent the performance of the models 
constructed for ADHF. A, ROC curve overlapping the clinical model and the clinical model plus the biomarker combination for RTI. 
The AUC increase is significant (P=0.048). B, ROC curve overlapping the clinical model and the clinical model plus the biomarker 
combination for RTI after the cross- validation. The AUC increase is significant (P=0.002). C, ROC curve overlapping the clinical 
model and the clinical model plus the biomarker combination for ADHF. The AUC increase is significant (P=0.038). D, ROC curve 
overlapping the clinical model and the clinical model plus the biomarker combination for RTI after the cross- validation. The AUC 
increase is significant (P=0.02). ADHF indicates acute decompensated heart failure; AUC, area under the curve; ROC, receiver 
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The study has certain limitations. First, the fact 
that data were collected by reviewing clinical regis-
tries might lead to some missing data. In fact, the 
incidence of ADHF in our study is much lower than 
reported. Second, the low number of events in the 
case of ADHF, even after the use of Firth correction, 
leads to wide CIs for the combination of blood bio-
markers, making these results less reliable. Third, 
data on previous history of HF were not available and, 
therefore, we cannot rule out whether the predictive 
value of the biomarker panels might be modified 
by the existence of previous HF. Likewise, relevant 
data related to RTI were also not available, such as 
dysphagia or severe facial palsy at admission. An 
external validation or replication of our results has 
not been possible because of the inability to obtain 
a large cohort of stroke patients with acute blood 
samples. Furthermore, the clinical value added by 
the biomarkers combination in the clinical models is 
rather low. In addition, the use of study- derived cut-
off points for biomarker measurement, even when 
is automatically selected by the PanelomiX software 
and not driven by the investigators, might overes-
timate the precision of our observations. However, 
given the preliminary nature of the present study, 
the selected cutoffs might serve as a reference for 
replication purposes in further studies. Finally, the 
measured biomarkers had other intended uses; 
therefore, our scores might be improved using other 
biomarkers more related to our end points such as 
C- reactive protein,30 procalcitonin,31 or serum am-
yloid A for RTI32 or midregional proatrial natriuretic 
peptide, troponin, interleukin- 1 receptor– like 1 or 
galectin- 3 for ADHF.17
These limitations confer to our study a hypothesis- 
generating nature, and future studies are needed to 
establish the practical usefulness of those markers. 
These future prospective studies should include pa-
tients experiencing stroke at admission, collecting 
data of cardiac and respiratory symptoms, and, ide-
ally, serial measurements of the biomarker panels in 
all included patients, to determine the specificity and 
sensitivity of each combination for the prediction be-
tween both complications. Dyspnea should also be 
reported, to explore the capacity of the biomarker 
combinations to differentiate between the 2 condi-
tions in these patients. The measurement of specific 
biomarkers of each complication, as the commented 
in the previous paragraph, might help to improve the 
prediction capacity of the panels.
CONCLUSIONS
In conclusion, blood biomarkers could be useful for the 
early prediction of 2 of the major complications during 
the in- hospital stay of stroke patients: ADHF and RTI. 
Future studies should focus on the validation of these 
results as well as the discriminative power of the pan-
els in patients with dyspnea.
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